Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus MENRIUM 10 4.
Head-to-head clinical analysis: CLOBAZAM versus MENRIUM 10 4.
CLOBAZAM vs MENRIUM 10-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
None Documented
None Documented
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination
"The metabolism of Erythromycin can be decreased when combined with Clobazam."